Sun.Mar 10, 2024

article thumbnail

Blocking a Single Protein Could Prevent Nerve Damage Responsible For Alzheimer’s

AuroBlog - Aurous Healthcare Clinical Trials blog

Scientists have identified a key protein in the development of Alzheimer’s disease which could prove critical in slowing or even halting the condition’s progress.

Protein 180
article thumbnail

Lilly’s Alzheimer’s drug delayed as FDA seeks adcomm

pharmaphorum

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of the drug. Lilly said the US regulator “wants to further understand topics related to evaluating the safety and efficacy of donanemab,” which includes the safety and efficacy results of its pivotal TRAILBLAZER-ALZ 2 study.

Drugs 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ICMR takes ground-breaking efforts in infectious disease surveillance & capacity building

AuroBlog - Aurous Healthcare Clinical Trials blog

In a remarkable display of scientific prowess and commitment to public health, the Indian Council of Medical Research (ICMR) has spearheaded a series of ground-breaking initiatives aimed at tackling infectious diseases and bolstering diagnostic capabilities nationwide, according to its Annual Report 2023.

Research 167
article thumbnail

Approach to Obesity Treatment in Primary Care

JAMA Internal Medicine

This review provides guidance on the treatment of obesity in adults, including lifestyle interventions, antiobesity medications, and surgical approaches.

92
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

HP&M’s Larry Houck A Panelist at FDLI’s Cannabis Regulation Conference

FDA Law Blog

Last August the Food and Drug Administration (“FDA”)/Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule cannabis from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. By doing so, FDA/HHS believe that cannabis no longer meets schedule I criteria but does not meet schedule II criteria either.

article thumbnail

Clinical Decision Support for Hypertension Management in Chronic Kidney Disease

JAMA Internal Medicine

This randomized clinical trial evaluates a computerized clinical decision support system for the management of uncontrolled hypertension in patients with chronic kidney disease.

More Trending

article thumbnail

What Should I Know About Injectable Weight-Loss Medications?

JAMA Internal Medicine

This JAMA Internal Medicine Patient Page describes how to use injectable weight-loss medications as well as their risks and benefits.

article thumbnail

Women’s Health Matters! Join This Menopausal Depression Research Study!

Trialfacts

Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center Study Location Research Center: The University of Texas Southwestern Medical Center Location: 1440 Empire Central Drive, Ste LD4.100, Dallas, TX 75247 Lead Researchers: Sherwood Brown, MD, PhD, MBA and Marlene Freeman, MD IRB: This study has been reviewed and approved by the UT Southwestern Medical Center Institutional Review Board About the Study A number of women grapple with

article thumbnail

Which pharmaceutical drugs have the most drug patents in Netherlands?

Drug Patent Watch

This chart shows the drugs with the most patents in Netherlands. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Netherlands? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59